Monjuvi, Minjuvi(tafasitamab)
Minjuvi, Monjuvi (tafasitamab) is an antibody pharmaceutical. Tafasitamab was first approved as Monjuvi on 2020-07-31. It is used to treat large b-cell lymphoma diffuse in the USA. It has been approved in Europe to treat large b-cell lymphoma diffuse. The pharmaceutical is active against B-lymphocyte antigen CD19.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| hemic and lymphatic diseases | D006425 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Monjuvi
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| monjuvi | Biologic Licensing Application | 2024-05-31 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| large b-cell lymphoma diffuse | — | D016403 | C83.3 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
tafasitamab, Monjuvi, MorphoSys US Inc. | |||
| 2027-07-31 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9349 | Injection, tafasitamab-cxix, 2 mg |
Clinical
Clinical Trials
50 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 3 | 5 | — | — | 1 | 7 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 2 | 2 | — | — | 1 | 4 |
| B-cell lymphoma | D016393 | — | — | 2 | 2 | — | — | 1 | 4 |
| Leukemia | D007938 | — | C95 | — | 3 | — | — | — | 3 |
| Lymphoid leukemia | D007945 | — | C91 | — | 3 | — | — | — | 3 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | — | 2 | — | — | — | 2 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | — | 1 | — | — | — | 1 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | — | 1 | — | — | — | 1 |
| Prolymphocytic leukemia | D015463 | — | — | — | 1 | — | — | — | 1 |
| Mantle-cell lymphoma | D020522 | — | — | 1 | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tafasitamab |
| INN | tafasitamab |
| Description | Tafasitamab, sold under the brand name Monjuvi, is a medication used in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1422527-84-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4298047 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB15044 |
| UNII ID | QQA9MLH692 (ChemIDplus, GSRS) |
Target
Agency Approved
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Minjuvi – Incyte
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 598 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,779 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use